{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:51:43Z","timestamp":1787014303575,"version":"build-2736575974"},"reference-count":31,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Adherence to antiretroviral treatment (ART) plays a key role in achieving viral suppression in people living with HIV. We aimed to quantify ART adherence in the entire French HIV\u2010infected population treated in 2019 and to determine factors of influence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      People living with HIV were identified using HIV diagnosis according to\n                      <jats:italic>International Statistical Classification of Diseases and Related Health Problems, Tenth Revision<\/jats:italic>\n                      criteria, HIV\u2010specific laboratory tests, and prescription of antiretrovirals in 2019. Adherence was measured using the medication possession ratio (MPR; actual divided by theoretical number of tablets). Variables of interest included sex, age, type of ART, relevant comorbidities, and receiving supplementary universal health coverage for low\u2010income citizens (CMUc).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009211\u2009124 people living with HIV identified between 2006 and 2019, we included\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009140\u2009607 on ART with two or more prescription fills in 2019 in this analysis. In total, 87.5% of people living with HIV were receiving ART in 2019. Mean \u00b1 standard deviation MPR was 82.5\u2009\u00b1\u200922.7%; 57% of people living with HIV had an MPR \u226590%, and 12.7% had an MPR &lt;50%. Those with an MPR \u226590% significantly differed between males and females (59.1% and 52.8%, respectively;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and between CMUc recipients and non recipients\u00a0(54.1% and 57.6%, respectively;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). MPR \u226590% rate was lower for those with chronic nephropathy (50.2%), renal failure (46.6%), and tuberculosis (50.1%), and for those using psychoactive substances (52.3%). Factors associated with MPR \u226590% in multivariable analysis were older age, male sex, not receiving CMUc, more recent HIV diagnosis, and triple (vs. dual) ART.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In 2019, the average MPR in people living with HIV was 82.5% according to the comprehensive French health care database. Besides sociodemographic variables such as older age, male sex, and not being a CMUc recipient (i.e. of low socioeconomic status), more recent HIV diagnosis and triple therapy were independently associated with better adherence, possibly reflecting advances in ART tolerability and dosing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.13690","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T07:22:32Z","timestamp":1725520952000},"page":"1218-1226","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of HIV antiretroviral treatment adherence in 2019 using anonymized data from the\n                    <scp>French<\/scp>\n                    national health insurance claims data base: The\n                    <scp>COCOVIH<\/scp>\n                    study"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2223-7121","authenticated-orcid":false,"given":"F.","family":"Prevoteau du Clary","sequence":"first","affiliation":[{"name":"H\u00f4pital La Grave, Toulouse University Hospital \u2013 Centre de Sant\u00e9 Sexuelle, Cit\u00e9 de la sant\u00e9, Clinical Care  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Majerholc","sequence":"additional","affiliation":[{"name":"Foch Hospital, Clinical Care  Suresnes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Zucman","sequence":"additional","affiliation":[{"name":"Foch Hospital, Clinical Care  Suresnes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010M.","family":"Livrozet","sequence":"additional","affiliation":[{"name":"H\u00f4pital Edouard Herriot, Clinical Care  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vallee","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, Foch Hospital  Suresnes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Laurendeau","sequence":"additional","affiliation":[{"name":"CEMKA, RWE, Bourg\u2010La\u2010Reine  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bouee","sequence":"additional","affiliation":[{"name":"CEMKA, RWE, Bourg\u2010La\u2010Reine  France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"UNAIDS. 2025 AIDS TARGETS [Internet]. [cited 2022 Nov 1]. Available from:https:\/\/aidstargets2025.unaids.org\/"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq243"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.6.679"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1521\/aeap.2014.26.6.521"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7100328"},{"issue":"47","key":"e_1_2_11_7_1","first-page":"1618","article-title":"Vital signs: HIV prevention through care and treatment \u2013 United States","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_11_8_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2023 Mar 23 [cited 2023 Apr 11]; Available from:https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv"},{"key":"e_1_2_11_9_1","volume-title":"HIV and AIDS Estimates","author":"UNAIDS","year":"2021"},{"key":"e_1_2_11_10_1","volume-title":"HIV Diagnoses in France 2009\u20132020","author":"Michas, Fr\u00e9d\u00e9ric","year":"2022"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckae031"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2018.09.072"},{"key":"e_1_2_11_13_1","unstructured":"Graphiques Rapport\u2010Retour d'informations clinico\u2010\u00e9pid\u00e9miologiques (RICE) en France en2020[Internet]. Available from:https:\/\/anrs-co4.fhdh.fr\/rapport-retour-dinformations-clinico-epidemiologiques-rice-en-france-en-2020\/"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002142"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003234"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01883-8"},{"issue":"1","key":"e_1_2_11_17_1","article-title":"Adherence to antiretroviral therapy for HIV\/AIDS in Latin America and the Caribbean: systematic review and meta\u2010analysis","volume":"21","author":"Costa J de M","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.4103\/0970-0218.112435"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2010.10.016"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-011-9942-x"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21081-x"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2019.0278"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-021-00405-4"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-018-2303-2"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.844685"},{"issue":"2","key":"e_1_2_11_26_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212744","article-title":"Antiretroviral adherence and virologic suppression in partnered and unpartnered HIV\u2010positive individuals in southern Brazil","volume":"14","author":"Melo MG","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"e_1_2_11_27_1","first-page":"809","article-title":"Comparison of adherence rates for antiretroviral, blood pressure, or mental health medications for HIV\u2010positive patients at an academic medical center outpatient pharmacy","volume":"20","author":"Langness J","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/13548506.2014.945601"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00100-4"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020933772"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000243112.91293.26"},{"key":"e_1_2_11_32_1","unstructured":"EACS x\u2010European AIDS Clinical Society.Guidelines Clinical Management and Treatment of HIV Infected Adults in Europe. Version 5 [Internet]2009Available from:https:\/\/www.eacsociety.org\/media\/2009_eacsguidelines-v5-english.pdf"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T19:55:24Z","timestamp":1731354924000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/hiv.13690"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13690","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"2023-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}